EA201792547A1 - Популяции бактерий для стимуляции состояния здоровья - Google Patents

Популяции бактерий для стимуляции состояния здоровья

Info

Publication number
EA201792547A1
EA201792547A1 EA201792547A EA201792547A EA201792547A1 EA 201792547 A1 EA201792547 A1 EA 201792547A1 EA 201792547 A EA201792547 A EA 201792547A EA 201792547 A EA201792547 A EA 201792547A EA 201792547 A1 EA201792547 A1 EA 201792547A1
Authority
EA
Eurasian Patent Office
Prior art keywords
health condition
bacteria populations
stimulating health
stimulating
bacteria
Prior art date
Application number
EA201792547A
Other languages
English (en)
Inventor
Эран Сегал
Эран Элинав
Original Assignee
Иеда Рисеч Энд Девелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иеда Рисеч Энд Девелопмент Ко. Лтд. filed Critical Иеда Рисеч Энд Девелопмент Ко. Лтд.
Publication of EA201792547A1 publication Critical patent/EA201792547A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложен способ улучшения глюкозного ответа у субъектов с непереносимостью глюкозы. Способ предусматривает введение субъекту пробиотических композиций или средств, которые специфически снижают количество видов бактерий.
EA201792547A 2015-05-21 2016-05-17 Популяции бактерий для стимуляции состояния здоровья EA201792547A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562164684P 2015-05-21 2015-05-21
US201562256771P 2015-11-18 2015-11-18
PCT/IL2016/050520 WO2016185469A1 (en) 2015-05-21 2016-05-17 Bacterial populations for promoting health

Publications (1)

Publication Number Publication Date
EA201792547A1 true EA201792547A1 (ru) 2018-04-30

Family

ID=56117917

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792547A EA201792547A1 (ru) 2015-05-21 2016-05-17 Популяции бактерий для стимуляции состояния здоровья

Country Status (14)

Country Link
US (2) US20180140648A1 (ru)
EP (1) EP3297727A1 (ru)
JP (1) JP2018515564A (ru)
KR (1) KR20180010237A (ru)
CN (1) CN107847531A (ru)
AU (1) AU2016263293A1 (ru)
BR (1) BR112017024928A2 (ru)
CA (1) CA2986203A1 (ru)
EA (1) EA201792547A1 (ru)
HK (1) HK1245172A1 (ru)
IL (1) IL255788A (ru)
MX (1) MX2017014787A (ru)
WO (1) WO2016185469A1 (ru)
ZA (1) ZA201707930B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3138031T3 (pl) 2014-04-28 2023-04-11 Yeda Research And Development Co., Ltd. Sposób i urządzenie do przewidywania odpowiedzi na pokarm
EP3881680A1 (en) 2014-10-31 2021-09-22 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
CN106974939B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
CA3047397A1 (en) * 2016-12-20 2018-06-28 The Regents Of The University Of California Compositions and methods for inhibiting seizures
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
WO2019002218A2 (en) * 2017-06-25 2019-01-03 Snipr Technologies Limited MODIFICATION OF MICROBIAL POPULATIONS AND MODIFICATION OF MICROBIOTA
JP2020529478A (ja) * 2017-08-04 2020-10-08 セカンド ゲノム インコーポレイテッド バイオ治療薬としてのロゼブリア・ホミニス（ｒｏｓｅｂｕｒｉａ ｈｏｍｉｎｉｓ）、ユーバクテリウム・エリゲンス（ｅｕｂａｃｔｅｒｉｕｍ ｅｌｉｇｅｎｓ）、およびこれらの組み合わせ
CA3072289A1 (en) 2017-08-06 2019-02-14 Second Genome, Inc. Streptococcus australis as a biotherapeutics
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
US11160837B2 (en) * 2017-09-15 2021-11-02 Bgi Shenzhen Megamonas funiformis and applications thereof
US11344584B2 (en) 2017-09-26 2022-05-31 Second Genome, Inc. Gemella sanguinis as a biotherapeutic
WO2020117997A1 (en) 2018-12-05 2020-06-11 The Procter & Gamble Company Container for personal health compositions
CN112888448B (zh) * 2018-12-07 2023-07-25 深圳华大生命科学研究院 单形巨单胞菌在预防和/或治疗代谢性疾病中的用途
GB201900744D0 (en) * 2019-01-18 2019-03-06 Mars Inc Monitoring tools and diagnostic methods
US12059441B2 (en) 2019-05-01 2024-08-13 International N&H Denmark Aps Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same
CA3148434A1 (en) * 2019-07-30 2021-02-04 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
AU2021246535A1 (en) * 2020-04-03 2022-10-27 International N&H Denmark Aps Composition comprising bacterial strains for improving metabolic health
FR3114743B1 (fr) 2020-10-07 2023-10-20 Institut National De Rech Pour L’Agriculture L’Alimentation Et L’Environnement Streptocoque pour utilisation dans le traitement de l’intolérance au glucose
CN114717339B (zh) * 2021-01-05 2024-04-05 深圳华大生命科学研究院 检测snp位点的试剂在制备试剂盒中的用途
CN112877254B (zh) * 2021-03-10 2022-06-03 闽江学院 一株内生克什米尔小陌生菌及其应用
CN114159475B (zh) * 2021-07-16 2022-09-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种细菌在制备免疫检查点抑制剂的增效剂中的应用
WO2023133461A1 (en) * 2022-01-07 2023-07-13 Lifemine Therapeutics, Inc. Computational method to identify gene networks containing functionally-related genes

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (en) 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
GB0001309D0 (en) 2000-01-20 2000-03-08 Nestle Sa Valve arrangement
EP2102350A4 (en) * 2006-12-18 2012-08-08 Univ St Louis INTESTINAL MICROBIOMA AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR OBESITY-RELATED DISORDER
ES2436251B1 (es) * 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
EP3016527B1 (en) * 2013-06-03 2018-07-25 Proprev AB Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella
CN104415061B (zh) * 2013-08-30 2016-06-01 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途

Also Published As

Publication number Publication date
BR112017024928A2 (pt) 2018-07-31
US20180140648A1 (en) 2018-05-24
WO2016185469A1 (en) 2016-11-24
EP3297727A1 (en) 2018-03-28
CA2986203A1 (en) 2016-11-24
US20200206283A1 (en) 2020-07-02
KR20180010237A (ko) 2018-01-30
ZA201707930B (en) 2019-02-27
CN107847531A (zh) 2018-03-27
MX2017014787A (es) 2018-05-01
HK1245172A1 (zh) 2018-08-24
JP2018515564A (ja) 2018-06-14
IL255788A (en) 2018-01-31
AU2016263293A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
EA202090728A1 (ru) Применение нор-урсодезоксихолевой кислоты для снижения печеночного жира
EP4328245A3 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
RU2015118637A (ru) Тени бактерий L. delbrueckii 76 для стимулирования врожденного иммунного ответа и их применение
RU2015118636A (ru) Тени бактерий L. casei 583 для стимулирования врожденного иммунного ответа и их применение